Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Cardiovascular Protection of Aspirin in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis

Author(s): Ting Chen, Yunlei Deng and Rong Gong*

Volume 22, Issue 4, 2024

Published on: 12 June, 2024

Page: [287 - 296] Pages: 10

DOI: 10.2174/1570161121666230530154647

Price: $65

Abstract

Purpose: To evaluate aspirin's cardiovascular (CV) protective effect in chronic kidney disease (CKD) patients.

Methods: We searched PubMed, Embase, Cochrane Library, and Web of Science (up to December 2022) for randomized controlled trials (RCTs) and observational studies comparing aspirin with placebo in CKD patients for the prevention of CV disease (CVD). Efficacy outcomes included CVD, heart failure, myocardial infarction, stroke, CV and all-cause mortality; safety outcomes included major bleeding, minor bleeding, and renal events.

Results: Six RCTs and 6 observational studies, including 35,640 participants, met the inclusion criteria and reported relevant CV outcomes, with a mean follow-up of 46.83 months. The pooled data showed aspirin had no significant preventive effect on CVD events (RR=1.03; 95% CI, 0.84-1.27). However, CV mortality was significantly reduced in the aspirin group (RR=0.74; 95% CI, 0.58-0.95). Furthermore, aspirin use did not increase the risk of major bleeding and renal events but significantly increased minor bleeding events (RR=2.11; 95% CI, 1.30-3.44). Renal events were significantly increased after sensitivity analysis (RR=1.10; 95% CI, 1.04-1.16).

Conclusion: Aspirin did not prevent CV events, with a significantly increased risk of minor bleeding and renal events. Besides, aspirin use had no statistically significant reduction in the risk of all-cause mortality but had a statistically significant reduction in the risk of CV mortality.

« Previous Next »
Graphical Abstract

[1]
Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020; 395(10225): 709-33.
[http://dx.doi.org/10.1016/S0140-6736(20)30045-3] [PMID: 32061315]
[2]
Baber U, Gutierrez OM, Levitan EB, et al. Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers. Am Heart J 2013; 166(2): 373-380.e2.
[http://dx.doi.org/10.1016/j.ahj.2013.05.008] [PMID: 23895822]
[3]
Masson P, Webster AC, Hong M, Turner R, Lindley RI, Craig JC. Chronic kidney disease and the risk of stroke: A systematic review and meta-analysis. Nephrol Dial Transplant 2015; 30(7): 1162-9.
[http://dx.doi.org/10.1093/ndt/gfv009] [PMID: 25681099]
[4]
Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015; 3(7): 514-25.
[http://dx.doi.org/10.1016/S2213-8587(15)00040-6] [PMID: 26028594]
[5]
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13): 1296-305.
[http://dx.doi.org/10.1056/NEJMoa041031] [PMID: 15385656]
[6]
Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65(3): 1009-16.
[http://dx.doi.org/10.1111/j.1523-1755.2004.00465.x] [PMID: 14871421]
[7]
Rysz J, Franczyk B, Ławiński J, Gluba-Brzózka A. Oxidative stress in ESRD patients on dialysis and the risk of cardiovascular diseases. Antioxidants 2020; 9(11): 1079.
[http://dx.doi.org/10.3390/antiox9111079] [PMID: 33153174]
[8]
Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30(5): 579-89.
[http://dx.doi.org/10.1055/s-2004-835678] [PMID: 15497100]
[9]
Adeseun GA, Xie D, Wang X, et al. Carotid plaque, carotid intima-media thickness, and coronary calcification equally discriminate prevalent cardiovascular disease in kidney disease. Am J Nephrol 2012; 36(4): 342-7.
[http://dx.doi.org/10.1159/000342794] [PMID: 23107930]
[10]
Saran R, Robinson B, Abbott KC, et al. US renal data system 2018 annual data report: Epidemiology of kidney disease in the United States. Am J Kidney Dis 2019; 73(S3): A7-8.
[http://dx.doi.org/10.1053/j.ajkd.2019.01.001] [PMID: 30798791]
[11]
Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141(S2): e419S-96S.
[http://dx.doi.org/10.1378/chest.11-2301]
[12]
Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physiciansevidence-based clinical practice guidelines. Chest 2012; 141(S2): e669S-90S.
[http://dx.doi.org/10.1378/chest.11-2307]
[13]
Dai Y, Ge J. Clinical use of aspirin in treatment and prevention of cardiovascular disease. Thrombosis 2012; 2012: 1-7.
[http://dx.doi.org/10.1155/2012/245037] [PMID: 22195280]
[14]
Fuster V, Sweeny JM. Aspirin. Circulation 2011; 123(7): 768-78.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.963843] [PMID: 21343593]
[15]
Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373(9678): 1849-60.
[http://dx.doi.org/10.1016/S0140-6736(09)60503-1] [PMID: 19482214]
[16]
Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010; 33(6): 1395-402.
[http://dx.doi.org/10.2337/dc10-0555] [PMID: 20508233]
[17]
Byrne RA, Colleran R. Aspirin for secondary prevention of cardiovascular disease. Lancet 2020; 395(10235): 1462-3.
[http://dx.doi.org/10.1016/S0140-6736(20)30799-6] [PMID: 32386577]
[18]
Dehmer SP, O’Keefe LR, Evans CV, Guirguis-Blake JM, Perdue LA, Maciosek MV. Aspirin use to prevent cardiovascular disease and colorectal cancer. JAMA 2022; 327(16): 1598-607.
[http://dx.doi.org/10.1001/jama.2022.3385] [PMID: 35471506]
[19]
Qu B, He Y, Wu L, Lu H, Wu H, Li M. Is there a cardiovascular protective effect of aspirin in chronic kidney disease patients? A systematic review and meta-analysis. Int Urol Nephrol 2020; 52(2): 315-24.
[http://dx.doi.org/10.1007/s11255-019-02350-8] [PMID: 31820360]
[20]
Pallikadavath S, Ashton L, Brunskill NJ, Burton JO, Gray LJ, Major RW. Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis. Eur J Prev Cardiol 2022; 28(17): 1953-60.
[http://dx.doi.org/10.1093/eurjpc/zwab132] [PMID: 34448849]
[21]
Mann JFE, Joseph P, Gao P, et al. Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease. Kidney Int 2023; 103(2): 403-10.
[http://dx.doi.org/10.1016/j.kint.2022.09.023] [PMID: 36341885]
[22]
Wolfe R, Wetmore JB, Woods RL, et al. Subgroup analysis of the ASPirin in reducing events in the elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney Int 2021; 99(2): 466-74.
[http://dx.doi.org/10.1016/j.kint.2020.08.011] [PMID: 32920022]
[23]
Oh YJ, Kim AJ, Ro H, et al. Low-dose aspirin was associated with an increased risk of cardiovascular events in patients with chronic kidney disease and low bodyweight: Results from KNOW-CKD study. Sci Rep 2021; 11(1): 6691.
[http://dx.doi.org/10.1038/s41598-021-86192-4] [PMID: 33758303]
[24]
Tsai MH, Liou HH, Huang YC, Lee TS, Chen M, Fang YW. Hazardous effect of low-dose aspirin in patients with predialysis advanced chronic kidney disease assessed by machine learning method feature selection. Health Care 2021; 9(11): 1484.
[http://dx.doi.org/10.3390/healthcare9111484] [PMID: 34828530]
[25]
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(S2): S1-S266.
[PMID: 11904577]
[26]
Higgins JPT, Altman DG, Gøtzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343(oct18 2): d5928.
[http://dx.doi.org/10.1136/bmj.d5928] [PMID: 22008217]
[27]
Zhang Y, Huang L, Wang D, Ren P, Hong Q, Kang D. The ROBINS‐I and the NOS had similar reliability but differed in applicability: A random sampling observational studies of systematic reviews/meta‐analysis. J Evid Based Med 2021; 14(2): 112-22.
[http://dx.doi.org/10.1111/jebm.12427] [PMID: 34002466]
[28]
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273(5): 408-12.
[http://dx.doi.org/10.1001/jama.1995.03520290060030] [PMID: 7823387]
[29]
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557-60.
[http://dx.doi.org/10.1136/bmj.327.7414.557] [PMID: 12958120]
[30]
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 2010; 1(2): 97-111.
[http://dx.doi.org/10.1002/jrsm.12] [PMID: 26061376]
[31]
Goicoechea M, de Vinuesa SG, Quiroga B, et al. Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: A multicenter randomized clinical trial (AASER Study). Cardiovasc Drugs Ther 2018; 32(3): 255-63.
[http://dx.doi.org/10.1007/s10557-018-6802-1] [PMID: 29943364]
[32]
Saito Y, Morimoto T, Ogawa H, et al. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: Subanalysis from the JPAD trial. Diabetes Care 2011; 34(2): 280-5.
[http://dx.doi.org/10.2337/dc10-1615] [PMID: 21270185]
[33]
Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: A post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 2010; 56(12): 956-65.
[http://dx.doi.org/10.1016/j.jacc.2010.02.068] [PMID: 20828648]
[34]
Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005; 45(3): 473-84.
[http://dx.doi.org/10.1053/j.ajkd.2004.11.015] [PMID: 15754269]
[35]
Liu J, Pan Y, Chen L, et al. Low-dose aspirin for prevention of cardiovascular disease in patients on hemodialysis: A 5-y prospective cohort study. Hemodial Int 2016; 20(4): 548-57.
[http://dx.doi.org/10.1111/hdi.12409] [PMID: 26932276]
[36]
Hsiao KC, Huang JY, Lee CT, Hung TW, Liaw YP, Chang HR. Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke. Eur J Intern Med 2017; 39: 63-8.
[http://dx.doi.org/10.1016/j.ejim.2016.11.009] [PMID: 27884500]
[37]
Dad T, Tighiouart H, Joseph A, et al. Aspirin use and incident cardiovascular disease, kidney failure, and death in stable kidney transplant recipients: A post hoc analysis of the folic acid for vascular outcome reduction in transplantation (FAVORIT) trial. Am J Kidney Dis 2016; 68(2): 277-86.
[http://dx.doi.org/10.1053/j.ajkd.2016.01.019] [PMID: 26947217]
[38]
Kim AJ, Lim HJ, Ro H, et al. Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease. PLoS One 2014; 9(8): e104179.
[http://dx.doi.org/10.1371/journal.pone.0104179] [PMID: 25093403]
[39]
Hernandez GT, Sippel M, Mukherjee D. Interrelationship between chronic kidney disease and risk of cardiovascular diseases. Cardiovasc Hematol Agents Med Chem 2013; 11(1): 38-43.
[http://dx.doi.org/10.2174/1871525711311010007] [PMID: 22721441]
[40]
Rhee TG, Kumar M, Ross JS, Coll PP. Age‐related trajectories of cardiovascular risk and use of aspirin and statin among U.S. adults aged 50 or older, 2011–2018. J Am Geriatr Soc 2021; 69(5): 1272-82.
[http://dx.doi.org/10.1111/jgs.17038] [PMID: 33598936]
[41]
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. J Am Coll Cardiol 2019; 74(10): e177-232.
[http://dx.doi.org/10.1016/j.jacc.2019.03.010] [PMID: 30894318]
[42]
Desai N, Wilson B, Bond M, Conant A, Rahman M. Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis. J Clin Hypertens 2021; 23(2): 352-62.
[http://dx.doi.org/10.1111/jch.14091] [PMID: 33340443]
[43]
Lim CC, Teo BW, Ong PG, et al. Chronic kidney disease, cardiovascular disease and mortality: A prospective cohort study in a multi-ethnic Asian population. Eur J Prev Cardiol 2015; 22(8): 1018-26.
[http://dx.doi.org/10.1177/2047487314536873] [PMID: 24857889]
[44]
van Kruijsdijk RCM, Visseren FLJ, Ridker PM, et al. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. Heart 2015; 101(5): 369-76.
[http://dx.doi.org/10.1136/heartjnl-2014-306342] [PMID: 25475110]
[45]
Huang MJ, Wei R, Wang Y, et al. Blood coagulation system in patients with chronic kidney disease: A prospective observational study. BMJ Open 2017; 7(5): e014294.
[http://dx.doi.org/10.1136/bmjopen-2016-014294] [PMID: 28576889]
[46]
Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events. JAMA 2019; 321(3): 277-87.
[http://dx.doi.org/10.1001/jama.2018.20578] [PMID: 30667501]
[47]
Boffa JJ, Just A, Coffman TM, Arendshorst WJ. Thromboxane receptor mediates renal vasoconstriction and contributes to acute renal failure in endotoxemic mice. J Am Soc Nephrol 2004; 15(9): 2358-65.
[http://dx.doi.org/10.1097/01.ASN.0000136300.72480.86] [PMID: 15339984]
[48]
White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension 2007; 49(3): 408-18.
[http://dx.doi.org/10.1161/01.HYP.0000258106.74139.25] [PMID: 17261646]
[49]
Fored CM, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345(25): 1801-8.
[http://dx.doi.org/10.1056/NEJMoa010323] [PMID: 11752356]
[50]
Gallagher H, Lown M, Fuat A, Roderick P. Aspirin for primary prevention of CVD in CKD: Where do we stand? Br J Gen Pract 2019; 69(689): 590-1.
[http://dx.doi.org/10.3399/bjgp19X706661] [PMID: 31780468]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy